Navigation Links
Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
Date:5/21/2012

KIRKLAND, Wash., May 21, 2012 /PRNewswire/ -- Cardiac Dimensions®, Inc. today announced that data from its landmark TITAN clinical trial has been published in the most recent issue of the European Journal of Heart Failure. Titled "Treatment of Functional Mitral Regurgitation by Percutaneous Annuloplasty: Results of the TITAN Trial," the manuscript features two-year follow-up data on patients implanted with the CARILLON® Mitral Contour System® as well as one-year follow-up on a non-implanted concurrent comparison group. The CARILLON system is a novel therapy for treating heart patients suffering from functional mitral regurgitation (FMR) and has CE Mark approval, enabling commercialization in Europe.

TITAN (Transcatheter Implantation of CARILLON Mitral Annuloplasty Device) was a prospective, non-randomized, double-arm study evaluating CARILLON in FMR patients. The trial was designed to build upon the foundational results established in the AMADEUS (CARILLON Mitral Annuloplasty Device European Union Study) feasibility study. Fifty-three patients were enrolled in TITAN with 36 patients implanted with the CARILLON device and 17 serving as a non-implanted comparison group. Enrolled patients represented a severely ill advanced heart failure population at baseline, with an average New York Heart Association classification of 3, an average left ventricular ejection fraction below 30 percent and an average mitral regurgitation grade of 3+ to 4+.

Key findings from the study were as follows:

  • Implanted patients demonstrated significant reductions in FMR as assessed by multiple quantitative measures, including regurgitant volume, which decreased from 34.5 plus or minus 11.5 ml to 17.4 plus or minus 12.4 ml through 12 months (p<0.001).
  • Implanted patients experienced significant reverse remodeling with left ventricular diastolic and systolic volumes decreasing through 12 months, compared to progressive left ventricular dilation among the comparison group.
  • Marked improvement in functional capacity was observed among implanted patients through 24 months with six-minute walk distances increasing by 131.9 plus or minus 80 meters (p<0.001).
  • A 30-day major adverse event rate of 1.9 percent was demonstrated on an intent-to-treat basis.
  • "From Cardiac Dimensions' inception, we have been focused on delivering a therapeutic modality that effectively addresses FMR via a safe and efficient percutaneous approach," stated David Reuter, M.D., Ph.D., Chief Medical Officer. "With the publication of the TITAN results, we now have substantial evidence that we have achieved this objective. Patients who suffer from FMR are a large and growing population with few viable options for treatment. This manuscript serves as a major step forward in establishing CARILLON as an important therapy, specifically targeted at this debilitating condition. The strength of the data reflects the clinical evolution of the technology and we are pleased to have partnered with some of the leading investigators in the field in achieving these results. As an organization, these data provide us with significant confidence as we initiate commercialization in Europe."

    About CARILLON® Mitral Contour System® Cardiac Dimensions' CARILLON Mitral Contour System combines a proprietary, implantable device with a percutaneous catheter delivery system. The implantable device consists of a proximal anchor and a distal anchor connected by a shaping ribbon. Utilizing the heart's natural structures, the device is intended to reduce mitral annulus dilatation upon deployment, thereby significantly reducing functional mitral regurgitation (FMR). Rapidly delivered via the venous vasculature, CARILLON has the potential to treat most heart failure patients in a minimally invasive fashion. Clinical data suggests that usage is associated with significant reduction in FMR, and significant improvement in functional capacity and quality of life.

    About Functional Mitral RegurgitationMore than 20 million people worldwide have heart failure, most of whom also suffer from functional mitral regurgitation (FMR). FMR typically results from the dilation of the left ventricle, which is the main pumping chamber in the heart. As the left ventricle increases in size, the mitral valve also expands. This dimensional increase leads to mitral regurgitation, which significantly reduces the amount of blood flow out of the left ventricle and on to the body and its organs. FMR has been associated with high rates of mortality, reduced functional capacity, poor quality of life and an increase in patient hospitalizations. Current mainstream therapies to address FMR are limited. A majority of patients become refractory to medical therapy over time and traditional surgical intervention is associated with high rates of operative morbidity and mortality.

    About Cardiac Dimensions®, Inc. Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company's initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. Cardiac Dimensions is based in Kirkland, Washington. For more information, visit the company's web site: http://www.cardiacdimensions.com.

    Cardiac Dimensions, CARILLON and Mitral Contour System are registered trademarks of Cardiac Dimensions, Inc. For further information contact: Cardiac Dimensions, Inc.Allen & Caron, Inc.Omari Bouknight

    Len Hall(425) 605-5960 

    (949) 474-4300


    '/>"/>

    SOURCE Cardiac Dimensions, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Personalized Medicine - The Genomic Revolution in Cardiac Care
    2. FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
    3. Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor
    4. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
    5. Study Shows Vernakalant Hydrochloride is Effective in Conversion to Normal Heart Rhythm in Atrial Fibrillation Patients Following Cardiac Surgery
    6. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
    7. Do-It-Yourself Cardiac Bypass Surgery: All You Need is Walking Shoes
    8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
    9. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
    10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
    11. Study Finds PCI Safe, Effective Despite Off-Site Cardiac Surgery
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/27/2016)... 27, 2016 Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that ... at two upcoming investor conferences: SeeThru Equity MicroCap ... New York City , NY When: ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, 109 ...
    (Date:5/26/2016)... TARE (Transarterial Radio-embolization) Using ... and Overall Decreased Use of Hospital Resource ... specialist healthcare company, has today announced the publication ... of ISPOR (International Society for Pharmacoeconomics and Outcomes ... using yttrium-90 glass microspheres is associated with cost ...
    (Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
    Breaking Medicine Technology:
    (Date:5/27/2016)... Killeen, Texas (PRWEB) , ... May 27, 2016 , ... ... with satisfying Army body fat composition regulations. This is the first time that ... are normally screened at least every six months to ensure they meet the prescribed ...
    (Date:5/27/2016)... , ... May 27, 2016 , ... ... scholarships to students studying complementary medicine. Allison Outerbridge is this year’s Life ... award on May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge ...
    (Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook ... Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the ... is their favorite way to cook a hot dog, far outpacing other cooking methods ...
    (Date:5/26/2016)... Missouri (PRWEB) , ... May 26, 2016 , ... ... quality and clinical outcomes, hosted members and suppliers for its inaugural Member Conference ... focus on their mission of elevating the operational health of America’s healthcare providers. ...
    (Date:5/26/2016)... Washington, D.C. (PRWEB) , ... May 26, 2016 , ... ... the men and women who lost their lives in military battle for the country. ... discount cards in 2015 to provide more programs that empower independence for disabled military ...
    Breaking Medicine News(10 mins):